Tags

Type your tag names separated by a space and hit enter

Inhibitory action of somatostatin on pancreatic alpha and beta cell function.
J Clin Endocrinol Metab. 1975 Apr; 40(4):568-72.JC

Abstract

In normal men, the administration of somatostatin almost completely abolished the glucose stimulated insulin-release seen during control studies (without somatostatin), and caused a further reduction in glucagon secretion beyond that induced by hyperglycemia. Following the infusion, there was a rapid and marked rebound for insulin but not glucagon secretion. These events were attended by a marked retardation of the glucose disappearance rate (K) which exhibited two clearly separable components; the initial slow component (mean K equals 0.64) coincided with the period of insulin suppression and was followed by a faster component (mean K equals 1.37) temporally related to the marked rebound increase in insulin release after discontinuation of the somatostatin infusion. Similarly, the addition of somatostatin infusion completely blocked the release of insulin and growth hormone and delayed the release of glucagon stimulated by arginine infusion. Following the somatostatin infusion there was a small rise in GH and a marked rebound for insulin and this was associated with a higher level of plasma glucose than that found following arginine infusion alone. These data establish that the administration of somatostatin can effectively block the release of insulin stimulated by arginine and glucose, can attenuate the release of glucagon induced by arginine and can enhance the glucose-mediated glucagon suppression. The attendance of a relative hyperglycemia during these events is probably the net result of an impediment in peripheral glucose disposition due to acute insulin lack and a decreased hepatic glucose output secondary to glucagon suppression.

Authors

Leblanc H
No affiliation info available
Anderson JR
No affiliation info available
Sigel MB
No affiliation info available
Yen SS
No affiliation info available

MeSH

AdultArginineBlood GlucoseDrug InteractionsFemaleGlucagonGlucoseGrowth HormoneHumansInjections, IntravenousInsulinInsulin SecretionIodine RadioisotopesIslets of LangerhansMaleRadioimmunoassaySomatostatin

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1092707

Citation

Leblanc, H, et al. "Inhibitory Action of Somatostatin On Pancreatic Alpha and Beta Cell Function." The Journal of Clinical Endocrinology and Metabolism, vol. 40, no. 4, 1975, pp. 568-72.
Leblanc H, Anderson JR, Sigel MB, et al. Inhibitory action of somatostatin on pancreatic alpha and beta cell function. J Clin Endocrinol Metab. 1975;40(4):568-72.
Leblanc, H., Anderson, J. R., Sigel, M. B., & Yen, S. S. (1975). Inhibitory action of somatostatin on pancreatic alpha and beta cell function. The Journal of Clinical Endocrinology and Metabolism, 40(4), 568-72.
Leblanc H, et al. Inhibitory Action of Somatostatin On Pancreatic Alpha and Beta Cell Function. J Clin Endocrinol Metab. 1975;40(4):568-72. PubMed PMID: 1092707.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibitory action of somatostatin on pancreatic alpha and beta cell function. AU - Leblanc,H, AU - Anderson,J R, AU - Sigel,M B, AU - Yen,S S, PY - 1975/4/1/pubmed PY - 1975/4/1/medline PY - 1975/4/1/entrez SP - 568 EP - 72 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 40 IS - 4 N2 - In normal men, the administration of somatostatin almost completely abolished the glucose stimulated insulin-release seen during control studies (without somatostatin), and caused a further reduction in glucagon secretion beyond that induced by hyperglycemia. Following the infusion, there was a rapid and marked rebound for insulin but not glucagon secretion. These events were attended by a marked retardation of the glucose disappearance rate (K) which exhibited two clearly separable components; the initial slow component (mean K equals 0.64) coincided with the period of insulin suppression and was followed by a faster component (mean K equals 1.37) temporally related to the marked rebound increase in insulin release after discontinuation of the somatostatin infusion. Similarly, the addition of somatostatin infusion completely blocked the release of insulin and growth hormone and delayed the release of glucagon stimulated by arginine infusion. Following the somatostatin infusion there was a small rise in GH and a marked rebound for insulin and this was associated with a higher level of plasma glucose than that found following arginine infusion alone. These data establish that the administration of somatostatin can effectively block the release of insulin stimulated by arginine and glucose, can attenuate the release of glucagon induced by arginine and can enhance the glucose-mediated glucagon suppression. The attendance of a relative hyperglycemia during these events is probably the net result of an impediment in peripheral glucose disposition due to acute insulin lack and a decreased hepatic glucose output secondary to glucagon suppression. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/1092707/Inhibitory_action_of_somatostatin_on_pancreatic_alpha_and_beta_cell_function_ DB - PRIME DP - Unbound Medicine ER -